Friday, 20 Apr 2018

You are here

The RheumNow Week in Review – 9 June 2017

Dr. Jack Cush reviews the news and reports of interest from RheumNow in the last week:

  1. Abbvie Scholarship program accepting applications to award 15 grants ($15k/yr) to Students with Rheumatic disorders https://t.co/lgDLQRznJN
  2. Using Claims data, Allopurinol associated with lower risk of incident renal disease (HR 0.61) compared to febuxostat https://t.co/iGUKB4MxK0
  3. SLE myositis more likely to have rash, alopecia, pericarditis, vasculitis, Sm, RNP, dsDNA, low Plts & WBC, low C3.C4 https://t.co/UwWVr1XuhY
  4. Autoimmune diseases w/ MYOCARDITIS include sarcoidosis, Behçets, Churg-Strauss, inflammatory myositis, SLE https://t.co/zb3LdzUL9G
  5. QUEST-RA study shows the average RA pt has 2+ comorbidities (HTN, OP,OA); fatigue assoc w/ comorbidity & dz activity https://t.co/BPTsGW82ho
  6. Retro review of open label Tofacitinib 5 mg bid in 13 pts w/ alopecia areata showing ~50% regrowth after 4-5 mos https://t.co/Umw6vCOp3j
  7. Case reports showing tofacitinib, ruloxocitinb efficacy in difficult dermatomyositis, leads makers of JAK inhibitors to consider RCTs in DM
  8. Metormins effx mediated by change in gut microbiome; transfer of metformin-altered microbiota improves Glu tolerance https://t.co/1HvCnS19kW
  9. FDA Requests Removal of OPANA-ER from the Market 
  10. Debate over Alcohol and Methotrexate Precautions 
  11. Biosimilar Reports – May 2017
  12. Higher Fracture Risks with Prolonged Bisphosphonate Use in Older Women

 

 

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

The RheumNow Week in Review – Vitamin D Snark Report (4.20.18)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.  A second life for Syk kinase, Vitamin D talk, VTE, regulatory hearings and the Lupus clinic edge.

RheumNow Week in Review - Do you Dig Shingrix? (4.6.2018)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Highlights includes manpower shortfalls, comorbidities in AA Lupus, certolizumab pregnancy safety, which Shingles vaccine is best and the power of combination biologics in severe refractory  SLE.

"Breakthrough" Drug Designation by the FDA

The current issue of the NEJM reviews the Food and Drug Administration (FDA) “breakthrough therapy” designation that was introduced in 2012 to expedite testing and approval of medications that were intended to treat serious or life-threatening conditions.  This status is granted when preliminary evidence with a new drug suggests substantial benefits over existing therapies for these unfortunate conditions.

ACR Projects Significant Manpower Shortages for 2030

Arthritis & Rheumatology has published the results of the 2015 Workforce Study of Rheumatology Specialists, and estimates a current shortage (demand > supply) of 700 (12.9%) full-time rheumatologists and that this deficit will worsen (102%) to 4133 FTE by 2030.

RheumNow Week in Review -The Temporal Artery Biopsy Letdown (4.6.2018)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. News on the cost of RA care, infections on planes, CV events and Sacroiliitis in IBD, NXP-2 antibodies and calcinosis and rituximab in myositis ILD patients.